The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.
The Cystic Fibrosis Foundation is providing up to $5 million to develop a method to deliver a healthy copy of the CFTR gene into the lung cells of people with CF that is unlikely to trigger an immune system response.
Addressing variability in newborn screening can prevent missed diagnoses and delays in early care intervention.
CEO pledge is part of the Foundation’s ongoing commitment to strengthen the organization and better serve all people with CF
The cystic fibrosis care model is evolving to support people living longer with CF and their increasingly diverse health needs. Catalyzed by the approval of Trikafta® and the COVID-19 pandemic, this adaptive and personalized care model encompasses novel ways to connect clinicians and patients.
Marissa Benchea and Jeremy and Rachel Olimb to lead the Foundation’s volunteer advocacy base into a new chapter of CF
This milestone was reached nearly two years ahead of the initiative’s five-year commitment. However, the Foundation aims to continue to support infection research at the same pace as it has in the past three years.
The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.
The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.